Cargando…

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma

BACKGROUND: Our previous studies have identified CA916798 as a chemotherapy resistance-associated gene in lung cancer. However, the histopathological relevance and biological function of CA916798 in lung adenocarcinoma (LUAD) remains to be delineated. In this study, we further investigated and explo...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Jian, Lan, Xi, Liu, Xiayan, Deng, Caixia, Luo, Hu, Wang, Yan, Kang, Ping, Sun, Zhijian, Zhao, Lintao, Zhou, Xiangdong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035219/ https://www.ncbi.nlm.nih.gov/pubmed/36959566 http://dx.doi.org/10.1186/s12885-023-10735-3

Ejemplares similares

CA916798 gene expression is associated with multidrug resistance and predicts progression-free survival in patients with lung cancer
por: Duan, Hailing, et al.
Publicado: (2019)

Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798
por: Yang, Xuemei, et al.
Publicado: (2017)

Akt1 Enhances CA916798 Expression through mTOR Pathway
por: Wang, Yu-Liang, et al.
Publicado: (2013)

Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas
por: Wang, Jingshu, et al.
Publicado: (2017)

PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma
por: Zhang, Lina, et al.
Publicado: (2013)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas
por: Dai, Meng, et al.
Publicado: (2015)

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments
por: Zhao, Xiayan, et al.
Publicado: (2020)

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
por: WANG, ZHUN, et al.
Publicado: (2015)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
por: Zhou, Jianya, et al.
Publicado: (2015)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Linc00152 promotes Cancer Cell Proliferation and Invasion and Predicts Poor Prognosis in Lung adenocarcinoma
por: Zhang, Pei-pei, et al.
Publicado: (2017)

Poor Prognosis of Gastric Adenocarcinoma with Decreased Expression of AHRR
por: Li, Yuan-fang, et al.
Publicado: (2012)

Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma
por: Cai, Jinlian, et al.
Publicado: (2020)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients
por: Zou, Junyong, et al.
Publicado: (2022)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy
por: Fidler, M J, et al.
Publicado: (2011)

Aquaporin 1 Is an Independent Marker of Poor Prognosis in Lung Adenocarcinoma
por: Yun, Sumi, et al.
Publicado: (2016)

Decreased INPP5B expression predicts poor prognosis in lung adenocarcinoma
por: Deng, Jun, et al.
Publicado: (2022)

Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro
por: Li, Ya‐Qing, et al.
Publicado: (2017)

High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma
por: Chang, Sisi, et al.
Publicado: (2021)

CIP4 Promotes Lung Adenocarcinoma Metastasis and Is Associated with Poor Prognosis
por: Truesdell, P, et al.
Publicado: (2014)

Increased resistin suggests poor prognosis and promotes development of lung adenocarcinoma
por: Zhao, Cui-Cui, et al.
Publicado: (2018)

TGFBI Promoter Methylation is Associated with Poor Prognosis in Lung Adenocarcinoma Patients
por: Seok, Yangki, et al.
Publicado: (2019)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Transketolase Serves as a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma
por: Niu, Cong, et al.
Publicado: (2022)

High expression of DARS2 indicates poor prognosis in lung adenocarcinoma
por: Jiang, Yingfeng, et al.
Publicado: (2022)

NCAPG2 promotes tumour proliferation by regulating G2/M phase and associates with poor prognosis in lung adenocarcinoma
por: Zhan, Ping, et al.
Publicado: (2016)

UHRF1 predicts poor prognosis by triggering cell cycle in lung adenocarcinoma
por: Tu, Zhenbo, et al.
Publicado: (2020)

Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma
por: Jin, Jingchun, et al.
Publicado: (2012)

Claudin‐1 correlates with poor prognosis in lung adenocarcinoma
por: Sun, Bing‐sheng, et al.
Publicado: (2016)

Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
por: Liu, Yu-Tao, et al.
Publicado: (2015)

Elevated serum CA72-4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity-modulated radiation therapy
por: Liu, Peng, et al.
Publicado: (2015)

NUF2 Expression Promotes Lung Adenocarcinoma Progression and Is Associated With Poor Prognosis
por: Jiang, Feng, et al.
Publicado: (2022)

[Retracted] Increased resistin suggests poor prognosis and promotes development of lung adenocarcinoma
por: Zhao, Cui-Cui, et al.
Publicado: (2023)

Overexpression of MRPL19 in predicting poor prognosis and promoting the development of lung adenocarcinoma
por: Wei, Dong, et al.
Publicado: (2023)

Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma
por: Yang, Jian-Yu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8ofprao3ip5vfapsofpn0t7p0t